Clinical Trial

Postpartum Low-Dose Aspirin and Preeclampsia

Study Description

Postpartum Low-Dose Aspirin and Preeclampsia

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Aspirin

Low dose aspirin, 81mg tablets, PO

Drug - Placebo oral capsule

Placebo oral capsule, PO

Additional Information

Official Study Title

Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia

Clinical Trial ID

NCT03667326

ParticipAid ID

dL9ZAe